Healthcare-associated Gram-negative bloodstream infections: antibiotic resistance and predictors of mortality

Journal of Hospital Infection

Volumn 94, Issue 4, 2016, Pages 381-385

  Ergonul O ^a   Aydin, M ^b   Azap, A ^c   Basaran S ^d   Tekin, S ^a   Kaya, S ^e   Gulsun S ^e   Yoruk G ^f   Kursun E ^b   Yesilkaya A ^b   Simsek F ^g   Yilmaz E ^h   Bilgin, H ⁱ   Hatipoglu C ^j   Cabadak, H ^k   Tezer, Y ^k   Togan, T ^b   Karaoglan I ^l   Inan A ^m   Engin, A ⁿ   Aliskan H E ^b   Yavuz, S S ^d   Erdinc S ^j   Mulazimoglu, L ⁱ   Azap, O ^b   Can, F ^a   Akalin H ^h   Timurkaynak, F ^b   more..

^a KOÇ UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e Diyarbakir Training and Research Hospital   (Turkey)

^f ISTANBUL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^g OKMEYDANI TRAINING AND RESEARCH HOSPITAL   (Turkey)

^h ULUDAG UNIVERSITY   (Turkey)

ⁱ MARMARA UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^j ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^k Ankara Research Hospital   (Turkey)

^l GAZIANTEP UNIVERSITY   (Turkey)

^m GATA HAYDARPASA TRAINING HOSPITAL   (Turkey)

ⁿ CUMHURIYET UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

more..

Author keywords

Bloodstream; Gram negative; Healthcare

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CARBAPENEM; CEPHALOSPORIN; COLISTIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ADULT; APACHE; ARTICLE; BLOODSTREAM INFECTION; CAUSE OF DEATH; CENTRAL VENOUS CATHETER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE INFECTION; HEALTHCARE ASSOCIATED INFECTION; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MORTALITY RATE; MULTICENTER STUDY; NONHUMAN; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; TURKEY (REPUBLIC); VENTILATOR ASSOCIATED PNEUMONIA; AGED; ANTIBIOTIC RESISTANCE; BACTEREMIA; CLASSIFICATION; CLINICAL TRIAL; CROSS INFECTION; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PREVALENCE; PROGNOSIS; RISK FACTOR; SURVIVAL ANALYSIS; TURKEY;

ADULT; AGED; BACTEREMIA; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TURKEY;

EID: 84996899090     PISSN: 01956701     EISSN: 15322939     Source Type: Journal    
DOI: 10.1016/j.jhin.2016.08.012     Document Type: Article

References (17)

1. 1 Vincent, J.L., Nosocomial infections in adult intensive-care units. Lancet 361 (2003), 2068–2077.
2. 2 Guh, A.Y., Bulens, S.N., Mu, Y., et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012–2013. JAMA 314 (2015), 1479–1487.
3. 3 Canton, R., Akova, M., Carmeli, Y., et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 18 (2012), 413–431.
4. 4 Gray, J.W., Mahida, N., How do you solve a problem like multidrug-resistant Gram-negative bacteria?. J Hosp Infect 92 (2016), 1–2.
5. 5 Public Health Institute of Turkey, National hospital infections surveillance network, 2013 report., 2015, Public Health Institute of Turkey, Ankara.
6. 6 Horan, T.C., Andrus, M., Dudeck, M.A., CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36 (2008), 309–332.
7. 7 Clinical and Laboratory Standards Institute, Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. CLSI document M100-S20. 2010, CLSI, Wayne, PA.
8. 8 Kaye, K.S., Marchaim, D., Chen, T.Y., et al. Effect of nosocomial bloodstream infections on mortality, length of stay, and hospital costs in older adults. J Am Geriatr Soc 62 (2014), 306–311.
9. 9 Sligl, W.I., Dragan, T., Smith, S.W., Nosocomial Gram-negative bacteremia in intensive care: epidemiology, antimicrobial susceptibilities, and outcomes. Int J Infect Dis 37 (2015), 129–134.
10. 10 Martin-Loeches, I., Torres, A., Rinaudo, M., et al. Resistance patterns and outcomes in intensive care unit (ICU)-acquired pneumonia. Validation of European Centre for Disease Prevention and Control (ECDC) and the Centers for Disease Control and Prevention (CDC) classification of multidrug resistant organisms. J Infect 70 (2015), 213–222.
11. 11 Patel, G., Huprikar, S., Factor, S.H., Jenkins, S.G., Calfee, D.P., Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 29 (2008), 1099–1106.
12. 12 Hussein, K., Raz-Pasteur, A., Finkelstein, R., et al. Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect 83 (2013), 307–313.
13. 13 Altunsoy, A., Aypak, C., Azap, A., Ergonul, O., Balik, I., The impact of a nationwide antibiotic restriction program on antibiotic usage and resistance against nosocomial pathogens in Turkey. Int J Med Sci 8 (2011), 339–344.
14. 14 Ferrer, R., Martin-Loeches, I., Phillips, G., et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 42 (2014), 1749–1755.
15. 15 Wisplinghoff, H., Bischoff, T., Tallent, S.M., Seifert, H., Wenzel, R.P., Edmond, M.B., Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39 (2004), 309–317.
16. 16 European Centre for Disease Prevention and Control, Antimicrobial resistance surveillance in Europe 2013. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)., 2014, ECDC, Stockholm.
17. 17 Cai, Y., Chai, D., Wang, R., Liang, B., Bai, N., Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67 (2012), 1607–1615.